In 2021, Cytiva launched its inaugural Biopharma Resilience Index, which revealed how the biopharma industry is performing across five key pillars. It also provided clear recommendations for how the industry could forge a more resilient future.
To build on the success of the index, this year Cytiva has focused exclusively on one of the index pillars – Government Policy and Regulation. A survey of 500 senior biopharma executives worldwide reveals how greater government involvement in the industry during Covid-19 has affected areas such as the speed of drug approval, supply chain resilience and affordability of medication. It also highlights the key opportunities and risks around closer collaboration between government and biopharma.
In the articles, video and podcast on this page you can find out more about the data and hear directly from leaders across the biopharma and healthcare industries. These insights give both government and biopharma ways to further strengthen their relationship and safeguard public health in any future crisis.
From emergency to security: Healthcare collaboration in the post-Covid world
New research from Cytiva reveals that the urgency of combating Covid-19 drove closer collaboration between biopharma and government.
Better rules make better relationships
Covid-19 forced governments and biopharma companies to work together more than ever before, and at unprecedented speed, to approve products for the public good.
Growth beyond crisis: How can governments help their biopharma sectors to thrive?
From rapidly accelerated development and manufacturing to improved public-private sector collaboration, the impact of the pandemic on the biopharma sector has been nothing short of phenomenal.
CYTIVA’S 2021 GLOBAL BIOPHARMA RESILIENCE INDEX
Cytiva’s 2021 Global Biopharma Resilience Index - based on a survey of more than 1,000 senior biopharma executives - takes a holistic look at the industry across five key pillars: supply chain resilience, talent pool, R&D ecosystem, manufacturing agility, and government policy and regulation. The index scores reveal how the industry is performing in each area, highlighting new opportunities to grow and improve.
To dive into the highlights and key findings of the index, see the pillars headlining each article, and take a closer look at the interactive data visualisation below.
Making policy work for the biopharma industry
To deliver life-saving drugs more quickly, biopharma must work in harmony with governments and regulators.
Biopharma 2021: The resilience rethink
In an age of crisis, can the biopharma industry withstand global shocks?
Global or local? Biopharma's supply chain challenge
Drug shortages are common and is a reality that cannot be wished away.
Biopharma reaches for homegrown talent
Talent is particularly vital for pharma and biopharma, making a shallow pool of local talent a real issue.
Biopharma R&D needs more collaboration
Of all the lessons for Big Pharma from the Covid-19 pandemic, there is one that is likely to endure: collaboration.